Obsidian Therapeutics Inc.(OBX)

Biotechnology · Cambridge, MA

$13.88+0.04 (+0.29%)

Delayed quote: Oct 6, 2026, 11:25 AM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T15:28:03.379Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:28:03.379Z.

Quote observation: 2026-10-06T15:25:36.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 14,436,866
Total debt: N/A
Cash: N/A
TTM free cash flow: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

OBX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

OBX Competitors' EV/FCF Ratio

OBX

Obsidian Therapeutics Inc.

Current

Market Cap

$14.44M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLSM

Pulsenmore Ltd. Ordinary Shares

vs OBX

Market Cap

$14.24M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTXR

Citius Pharmaceuticals, Inc.

vs OBX

Market Cap

$14.02M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KPTI

Karyopharm Therapeutics Inc.

vs OBX

Market Cap

$15.03M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PASG

Passage Bio, Inc.

vs OBX

Market Cap

$13.78M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HIND

Vyome Holdings, Inc.

vs OBX

Market Cap

$13.34M

EV/FCF Ratio

10.42x

TTM Avg

13.15x

3Y Avg

13.15x

5Y Avg

13.15x

KTTA

Pasithea Therapeutics Corp.

vs OBX

Market Cap

$15.04M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INAB

IN8bio, Inc.

vs OBX

Market Cap

$13.71M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COCP

Cocrystal Pharma, Inc.

vs OBX

Market Cap

$15.58M

EV/FCF Ratio

N/A

TTM Avg

97.85x

3Y Avg

97.85x

5Y Avg

97.85x

ALLR

Allarity Therapeutics, Inc.

vs OBX

Market Cap

$15.75M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Obsidian Therapeutics Inc. (OBX)	$14.44M	N/A	N/A	N/A	N/A
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.24M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$14.02M	N/A	N/A	N/A	N/A
Karyopharm Therapeutics Inc. (KPTI)vs ›	$15.03M	N/A	N/A	N/A	N/A
Passage Bio, Inc. (PASG)vs ›	$13.78M	N/A	N/A	N/A	N/A
Vyome Holdings, Inc. (HIND)vs ›	$13.34M	10.42x	13.15x	13.15x	13.15x
Pasithea Therapeutics Corp. (KTTA)vs ›	$15.04M	N/A	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.71M	N/A	N/A	N/A	N/A
Cocrystal Pharma, Inc. (COCP)vs ›	$15.58M	N/A	97.85x	97.85x	97.85x
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.75M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

OBX EV/FCF Ratio Metrics

OBX Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics